The use of somatostatin analogues in a pregnant patient with gastric NET

#3737

Introduction: The question of the use of somatostatin analogues (ASS) during pregnancy remains open and requires further clarifications and observations, but based on the facts already known to us, we can suggest that, despite the fact that there are currently no adequate well-designed and well-controlled studies evaluating the use of ASS in pregnant women, there is enough data on a limited number of patients indicating on the absence of undesirable effects of ASS on the course of pregnancy or the health of the fetus/newborn.

Aim(s): Solving the issue of using ASS in pregnant women implies a thorough study of the effect of this groups of drugs on maternal and fetal health. It is also extremely important to understand whether for the introduction of ASS, that is the safest "therapeutic window".

Materials and methods: In St. Petersburg "City Clinical Oncological Dispensary" applied a 40-year-old female patient diagnosed with a neuroendocrine tumor of the stomach pT1N0M0 G1 stage I, endoscopic resection of the tumor (07.10.2021). Continued growth (+ biochemical relapse) dated 12.2021. Of the complications of the main diagnosis, carcinoid syndrome is noted. Regarding the recurrence of the disease and in order to control the carcinoid syndrome from December 2021, the patient was prescribed lanreotide 120 mg s.c. once every 28 days against the background of the control of Chromogranin A, Serotonin i and 5-Hydroxyindoleacetic acid every 2-3 months.

Conference:

Presenting Author: Androsova A

Authors: Androsova A, Orlova R, Ivanova A, Belyak N, Kutukova S,

Keywords: somatostatin analogues, Pregnancy, Neuroendocrine tumor,